Dr. Hussein Sweiti named enGene (NASDAQ: ENGN) chief medical officer

Rhea-AI Filing Summary

enGene Holdings Inc. filed a current report noting that it issued a press release on September 30, 2025 announcing the appointment of Dr. Hussein Sweiti as Chief Medical Officer. The press release is furnished, not filed, as Exhibit 99.1 and is not automatically incorporated into other securities filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001980845false00-00000000001980845us-gaap:CommonStockMember2025-09-302025-09-3000019808452025-09-302025-09-300001980845us-gaap:WarrantMember2025-09-302025-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2025

enGene Holdings Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia			001-41854	Not applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4868 Rue Levy, Suite 220
Saint-Laurent, Quebec, Canada				H4R 2P1
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 514 332-4888

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		ENGN		The Nasdaq Stock Market LLC
Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share		ENGNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

On September 30, 2025, the Company issued a press release announcing the appointment of Dr. Hussein Sweiti as Chief Medical Officer, a copy of which is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release of the Company dated September 30, 2025.
104		Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ENGENE HOLDINGS INC.
Date:	September 30, 2025	By:	/s/ Ronald H.W. Cooper
			Name: Ronald H.W. Cooper Title: Chief Executive Officer and President

FAQ

What did enGene (ENGN) disclose in this 8-K filing?

enGene disclosed that it issued a press release announcing the appointment of Dr. Hussein Sweiti as Chief Medical Officer. The press release is attached as Exhibit 99.1 and is furnished under Regulation FD, not filed for liability purposes.

Who was appointed Chief Medical Officer at enGene (ENGN)?

enGene appointed Dr. Hussein Sweiti as its Chief Medical Officer. The appointment was announced via a company press release dated September 30, 2025, which is included with the report as Exhibit 99.1 under Regulation FD disclosure rules.

How is the press release treated in enGene’s 8-K?

The press release announcing Dr. Sweiti’s appointment is furnished, not filed, under Item 7.01. This means it is not subject to Section 18 liability and is only incorporated into other securities filings if specifically referenced there.

Which exhibits are included with enGene (ENGN)’s 8-K?

The report includes Exhibit 99.1, the press release dated September 30, 2025 announcing the new Chief Medical Officer, and Exhibit 104, the cover page interactive data file formatted as Inline XBRL, which provides the required structured data for the cover information.

Does this enGene 8-K contain financial results or transaction details?

No, this report focuses on a management-related press release. It addresses the appointment of Dr. Hussein Sweiti as Chief Medical Officer and provides related exhibits, without presenting financial results, major transactions, or changes to the company’s capital structure.